Ed oversees Lilly Ventures operations and brings 26 years of pharmaceutical and venture capital experience to the team. Since co-founding Lilly Ventures, he has led the investments in, and previously served on the boards of, Serenex (acquired by Pfizer), Coherus BioSciences (CHRS:NASDAQ), Conforma Therapeutics (acquired by Biogen Idec), Cabrellis Pharmaceuticals (acquired by Pharmion Corporation) and Fluidigm (FLDM:NASDAQ). Ed currently sits on the boards of GlobeImmune (GBIM:NASDAQ), Innocrin Therapeutics, Receptos (RCPT:NASDAQ), Viamet Pharmaceuticals and various non-profit institutions.
Prior to his role in Lilly Ventures, Ed had a diverse set of experiences throughout the domestic and international pharmaceutical businesses including operational finance, planning, M&A, business development and global marketing roles. Ed received a bachelors of arts from Creighton University and a master of business administration from the University of Michigan Business School, where he was a Consortium Fellow.